Vishal Gohil, a professor of biochemistry and biophysics at Texas A&M University, has been awarded the 2024 Ivano Bertini Award at the 13th International Copper Conference.
The award acknowledges Gohil for his team's discovery that the anti-cancer drug elesclomol could effectively deliver copper into cells, a critical step in the treatment of diseases caused by copper deficiency, such as Menkes disease.
Their study, published in the Proceedings of the National Academy of Sciences, showed that elesclomol aids copper delivery to essential enzymes, even in the absence of certain mitochondrial proteins. This discovery has significant therapeutic potential, leading to the first approved use of a copper-transporting drug in treating Menkes disease.
“I am greatly honored to receive the Ivano Bertini award,” Gohil said. “This recognition not only highlights the importance of our work in mitochondrial copper biology but also serves as a reminder of the potential that fundamental research has in transforming lives.”
Gohil’s achievements include being named a 2024 Fellow of Texas A&M’s Chancellor’s Enhancing Development and Generating Excellence in Scholarship program. He has also received the Chairman’s Prize from the United Mitochondrial Disease Foundation and the Martin Research Prize for Excellence in Basic Research from Massachusetts General Hospital.
The Ivano Bertini Award is named after the Italian bioinorganic chemist and recognizes researchers whose work advances copper biology, a critical field in understanding human health and disease.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login